10times
Conference

Novel Vaccines

24 - 25 Aug 2015 New Date Reminder
Boston Marriott Long Wharf, Boston, USA
AboutFollowers 2ExhibitorsSpeakers 60ReviewsPhotosTravel Deals

The Novel Vaccines, organized by the Cambridge Healthtech Institute will take place from 24th August to the 25th August 2015 at the Boston Marriott Long Wharf Hotel in Boston, United States Of America. The conference will cover areas like he conference will cover areas like create more efficacious vaccines and reduce costs, yet safety issues continue to arise, and challenges for developing new adjuvants persist.


Timings

07:15 AM - 05:00 PM (Aug 24) (General)
07:25 AM - 12:45 PM (Aug 25) (General)

Entry Fees

Paid Ticket Check Official Website

Estimated Turnout

100 - 500
Delegates
Based on previous editions

Category & Type

Conference
Medical & Pharma

Editions

Aug 2015
+1 more edition

Frequency Annual

Official Links

WebsiteContacts


Report Error
Claim this event

Organizer

Logo Follow Company

Cambridge Innovation Institute

USA620 Total Events / 119 Upcoming Events206+ Followers

Followers [ Users who have shown interest for this Event ]

Write a Review

Add Your Review

Speakers

Schedule & Agenda

Mon, 24 Aug 07:15 AM - 08:10 AM
Registration & Morning Coffee
Mon, 24 Aug 08:10 AM - 08:15 AM
Chairpersonu2019s Opening Remarks
Tariq Ghayur, Ph.D., Distinguished Research Fellow, AbbVie Bioresearch Center
Mon, 24 Aug 08:15 AM - 09:00 AM
KEYNOTE PRESENTATION: PD-1 BLOCKADE: CURRENT STATUS AND FUTURE OPPORTUNITIES
Michael B. Atkins, M.D., Deputy Director, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
Mon, 24 Aug 09:00 AM - 09:30 AM
Current Insights on the PD-1/PD-L1 Axis as a Therapeutic Target in Oncology: A Biomarker
Kurt Schalper, M.D., Ph.D., Associate Research Scientist, Pathology, Yale University School of MedicineMonoclonal antibodies targeting the co-...continue reading
Mon, 24 Aug 09:30 AM - 10:00 AM
Coffee Break
Mon, 24 Aug 10:00 AM - 10:30 AM
Intellectual Property Review of Major Immunotherapy Targets: Non Composition of Matter Approaches to Developing Unique IP in Cancer Immunotherapy
Konstantin M. Linnik, Ph.D., Partner, Intellectual Property, Nutter, McClennen & Fish, LLPImmunoncology IP is crowded u2013 the number of drug...continue reading
Mon, 24 Aug 10:30 AM - 11:00 AM
New and Noteworthy Solid Tumor Indications for Checkpoint Inhibitors
Amit Mahipal, M.D., Medical Director, Clinical Research Unit; Assistant Member, H. Lee Moffitt Cancer Center & Research InstituteImmune checkp...continue reading
Mon, 24 Aug 11:00 AM - 11:30 AM
Targeting Immune Suppressive Microenvironment by Immune Checkpoint Blockade in Multiple Myeloma
Gu00fcllu00fc Topal Gu00f6rgu00fcn, Ph.D., Senior Research Scientist, Dana-Farber Cancer InstitutePD1/PD-L1-signaling promotes tumor growth wh...continue reading
Mon, 24 Aug 11:30 AM - 12:00 PM
Sponsored Presentation (Opportunity Available)
Mon, 24 Aug 12:00 PM - 01:25 PM
Luncheon Presentation: Breaking Down the Barriers to Immune Infiltration in the
Elizabeth Evans, Ph.D., Director, Oncology Research, Vaccinex Inc.The tumor stroma creates an immunosuppressive microenvironment that restrict...continue reading
Mon, 24 Aug 01:25 PM - 01:30 PM
Chairpersonu2019s Remarks
Paul D. Rennert, Founder & Principal, SugarCone Biotech Consultants LLC
Mon, 24 Aug 01:30 PM - 02:00 PM
Tumor Associated Macrophages and CD4 T Cells Have Non-redundant Roles in the Suppression of CD8 T Cell Infiltration into Melanoma
Susan Kaech, Ph.D., Associate Professor, Immunobiology, Yale University School of MedicineIn melanoma patients, ~60% of patients have Braf-V60...continue reading
Mon, 24 Aug 02:00 PM - 02:30 PM
Building a Robust Translational Sciences Platform for Tumor Immunotherapy: From Identification of New Targets to Patient Enrichment Strategies
Sriram Sathy, Ph.D., Director, Translational Sciences, Jounce TherapeuticsJounce is focused on developing cancer immunotherapies that are gear...continue reading
Mon, 24 Aug 02:30 PM - 03:00 PM
Local Endothelial Complement Activation Reverses Endothelial Anergy and Enables Effective T Cell Tumor Infiltration and Immunotherapy
Andrea Facciabene, Ph.D., Research Assistant Professor, Obstetrics and Gynecology, University of Pennsylvania School of MedicineCancer immune ...continue reading
Mon, 24 Aug 03:00 PM - 03:30 PM
Refreshment Break
Mon, 24 Aug 03:30 PM - 04:00 PM
Anti-Tumor Function of an Anti-iNKT TCR Monoclonal Antibody
Weiming Yuan, Ph.D., Assistant Professor, Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern CaliforniaInv...continue reading
Mon, 24 Aug 04:00 PM - 04:30 PM
The Next Generation of TIL Therapy using Immune Modulator Combinations
Laszlo Radvanyi, Ph.D., CSO, Lion BiotechnologiesThe use of autologous tumor-infiltrating lymphocytes (TIL) has made significant advances rece...continue reading
Mon, 24 Aug 04:30 PM - 05:00 PM
Immunomodulatory Antibody Targets in the Tumor Microenvironment
Paul D. Rennert, Founder & Principal, SugarCone Biotech Consultants LLCCTLA-4 and PD-1/PD-L1 antagonists target T cell immune checkpoint pathw...continue reading
Mon, 24 Aug 05:00 PM - 05:00 PM
End of Day
Tue, 25 Aug 07:25 AM - 07:55 AM
Morning Coffee
Tue, 25 Aug 07:55 AM - 08:00 AM
Chairpersonu2019s Opening Remarks
John Haurum, M.D., D.Phil., CEO, F-star GmbH & F-star Biotechnology Ltd.
Tue, 25 Aug 08:00 AM - 08:30 AM
Design and Construction of Tri- and Tetra-Specific Ig Molecules to Regulate T Cell Functions and Immune Responses
Tariq Ghayur, Ph.D., Distinguished Research Fellow, AbbVie Bioresearch CenterFour dual-variable-domain u2013 Ig (DVD-Igu2122) molecules are in...continue reading
Tue, 25 Aug 08:30 AM - 09:00 AM
Multivalent Antibody Therapeutics for Cancer Immunotherapy
Charles L. Sentman, Ph.D., Professor, Microbiology and Immunology; Director, Center for Synthetic Immunity, Geisel School of Medicine, Dartmou...continue reading
Tue, 25 Aug 09:00 AM - 09:30 AM
Immunomodulatory Bispecific Antibodies
Barbara Swanson, Ph.D., Director, Research, Sorrento Therapeutics, Inc.Using chemical and molecular biology techniques, Sorrento has developed...continue reading
Tue, 25 Aug 09:30 AM - 10:00 AM
Bispecific Antibodies Targeting Checkpoint Inhibitors
Mark Throsby, Ph.D., CSO, MerusThe Biclonicsu00ae platform is a robust and validated technology suite for the development of human full-length...continue reading
Tue, 25 Aug 10:15 AM - 10:15 AM
In vivo Efficacy of a Bispecific Molecule Targeting CTLA-4 and EGFR
Jacqueline Doody, Vice President, Immunology, F-star Biotechnology Ltd.A bispecific antibody was generated by engineering the constant region ...continue reading
Tue, 25 Aug 10:15 AM - 10:30 AM
Sponsored Presentation (Opportunity Available)
Tue, 25 Aug 10:30 AM - 11:15 AM
Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing
Tue, 25 Aug 11:15 AM - 12:15 PM
PLENARY KEYNOTE Dangerous Thoughts on Immunotherapy
Polly C. Matzinger, Ph.D. Senior Investigator, Ghost Lab, Laboratory of Immunogenetics, NAID/NIHWhat we think influences what we do. If we con...continue reading
Tue, 25 Aug 12:15 PM - 12:45 PM
Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
Tue, 25 Aug 12:45 PM - 12:45 PM
Close of Immunomodulatory Therapeutic Antibodies for Cancer
42.360189-71.050883

Venue Map & Directions

map of Boston Marriott Long Wharf

296 State St, Boston, MA 02109
USA

Get Directions

Featured Hotels in Boston